OTC monograph publication targets
This article was originally published in The Rose Sheet
Executive Summary
Notice of proposed rulemaking for UVA/UVB sunscreen products targeted for June 2002, FDA announces in unified agenda published in Federal Register Dec. 3. Estimated timeframe marks extension of previous September 2001 date, reflecting tentative nature of dates in biannual publication. Final action on healthcare antiseptic products expected by December 2002, rather than previous year-end 2001 goal. Possible near-term actions include release of skin protectants final monograph (listed as November 2001). Reproposal of skin bleaching products monograph expected by January 2003...
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.